Abstract:
The compounds of the invention are inhibitors of excitatory amino acid transporters (EAAT) that penetrate the blood-brain barrier to access the central nervous system. The compounds of the invention follow the structural formula: or a salt, ester or prodrug thereof, wherein X is a halogen, such as fluorine, or a radionuclide, such as fluorine-18. The compounds and methods described herein can be used for the treatment of, e.g., neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), ischemia, spinal cord injury, and traumatic brain injury in a patient (e.g., a human). The invention further provides compounds and methods for the synthesis and use of radiographic tracers to diagnose and follow the progression of such disorders.
Abstract:
Hydroxypolyamides, hydroxypolyamide products, and post-hydroxypolyamides are disclosed as gel forming agents. Hydroxypolyamides and post-hydroxypolyamides are prepared from known methods. Hydroxypolyamide products are produced from a modified polymerization procedure which utilizes strong base for deprotonation of ammonium salts from the esterification of stoichiometrically equivalent polyacid:polyamine salts. The hydroxypolyamide products are capable of gel formation at lower concentrations than hydroxypolyamides and post-hydroxypolyamides from the known methods of preparation, and are therefore superior gel forming agents.
Abstract:
The present invention is directed to novel inhibitors of system Xc−, also known as the cystine/glutamate antiporter. The present invention is further directed to methods of treating and detecting cancer that overexpresses system Xc− which includes but is not limited to gliomas (including glioblastoma), triple negative breast cancer, and bladder cancer. The present invention is further directed to methods of treating seizures including epileptic seizures.
Abstract:
A controlled nitric acid process employing oxygen and nitric acid as co-oxidants is used to oxidize organic compounds subject to nitric acid oxidation, to their corresponding carboxylic acids. Oxidation of some carbohydrates by this process can produce one or more of their corresponding acid forms. The process is carried out at moderate temperatures, typically in the range of 20° C. to 45° C. in a closed reactor, with oxygen gas being introduced into the reaction chamber as needed in order to sustain the reaction. Computer controlled reactors allow for careful and reproducible control of reaction parameters. Nitric acid can be recovered by a distillation/evaporation process, or by diffusion dialysis, the aqueous solution made basic with inorganic hydroxide, and the residual inorganic nitrate removed using a filtration (nanofiltration) device. The method eliminates issues of thermal control of the oxidation, release of nitrogen into the atmosphere, and post-reaction difficulties in the removal of nitric acid and inorganic nitrates.
Abstract:
The compounds of the invention are inhibitors of excitatory amino acid transporters (EAAT) that penetrate the blood-brain barrier to access the central nervous system. The compounds of the invention follow the structural formula: or a salt, ester or prodrug thereof, wherein X is a halogen, such as fluorine, or a radionuclide, such as fluorine-18. The compounds and methods described herein can be used for the treatment of, e.g., neurodegenerative disorders (e.g., amyotrophic lateral sclerosis), ischemia, spinal cord injury, and traumatic brain injury in a patient (e.g., a human). The invention further provides compounds and methods for the synthesis and use of radiographic tracers to diagnose and follow the progression of such disorders.
Abstract:
Real-time battery impedance spectra are acquired by stimulating a battery or battery system with a signal generated as a sum of sine signals at related frequencies. An impedance measurement device can be used to interface between the battery system and a host computer for generating the signals. The impedance measurement device may be calibrated to adapt the response signal to more closely match other impedance measurement techniques. The impedance measurement device may be adapted to operate at mid-range voltages of about 50 volts and high-range voltages up to about 300 volts.
Abstract:
Hydroxypolyamides, hydroxypolyamide products, and post-hydroxypolyamides are disclosed as gel forming agents. Hydroxypolyamides and post-hydroxypolyamides are prepared from known methods. Hydroxypolyamide products are produced from a modified polymerization procedure which utilizes strong base for deprotonation of ammonium salts from the esterification of stoichiometrically equivalent polyacid:polyamine salts. The hydroxypolyamide products are capable of gel formation at lower concentrations than hydroxypolyamides and post-hydroxypolyamides from the known methods of preparation, and are therefore superior gel forming agents.
Abstract:
Arabinogalactan compositions are provided which are useful in a wide variety of different biomedical applications. In one embodiment, water soluble lipidated arabinogalactans are provided which include arabinogalactan with a limited proportion of lipophilic groups, such as long-chain hydrocarbon groups, covalently attached to free hydroxyl groups on the arabinogalactan. The lipidated arabinogalactans are water soluble and biocompatible and are useful for a wide variety of different biomedical applications. The lipidated arabinogalactans can be used, for example, to inhibit cell adhesion, and to inhibit infection or inflammation. The lipidated arabinogalactans further may be used as adjuvants, to inhibit metastasis, and in other therapeutic applications.
Abstract:
Lipidated oxoadenines of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.